PHASE-II STUDY OF CIS-DIAMMINEDICHLOROPLATINUM IN PATIENTS WITH NON-SMALL CELL LUNG-CANCER
- 1 January 1985
- journal article
- research article
- Vol. 76 (5) , 420-423
Abstract
A phase II study of cis-diamminedichloroplatinum (CDDP, 80 mg/m2, every 3 wk) was performed in patients with non-small cell lung cancer (NSCLC). The overall response rate to CDDP was 14% (6/42). In patients without prior chemotherapy, the response rate was 20% (2/10) and in patients with prior chemotherapy, the response rate was 13% (4/31). The major side effect was gastrointestinal toxicity. It was concluded that CDDP at a dose of 80 mg/m2 every 3 wk is effective against NSCLC.This publication has 4 references indexed in Scilit:
- Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinomaCancer, 1982
- Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage SchedulesAnnals of Internal Medicine, 1981
- CIS-DICHLORODIAMMINEPLATINUM(II) ALONE FOLLOWED BY ADRIAMYCIN PLUS CYCLOPHOSPHAMIDE AT PROGRESSION VERSUS CIS-DICHLORODIAMMINEPLATINUM(II), ADRIAMYCIN, AND CYCLOPHOSPHAMIDE IN COMBINATION FOR ADENOCARCINOMA OF LUNG1978
- PHASE-2 EVALUATION OF CIS-DIAMMINEDICHLOROPLATINUM(II) IN LUNG-CANCER1976